CRPC w/ Bone Metastases VL

Effects of Ra-223 with Docetaxel vs. Docetaxel on PSA and Bone Alkaline Phosphatase - Charles Ryan

Details
Effects of Radium-223 Dichloride with Docetaxel versus Docetaxel on Prostate-specific Antigen and Bone Alkaline Phosphatase in Patients with Castration-resistant Prostate Cancer and Bone Metastases: A Phase 1/2a Clinical Trial Charles Ryan, MD presents the results of a study which has shown that the combination of radium-223 plus docetaxel appears to favorably impact posttreatment PSA and bone alk...

Use of Radium-223 for Symptomatic mCRPC with or without Prior Docetaxel - Oliver Sartor

Details
Efficacy and Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases, with or without Previous Docetaxel use: A Prespecified Subgroup Analysis from the Randomised, Double-blind, Phase 3 ALSYMPCA Trial Dr. Oliver Sartor presents the outcomes of a prespecified subgroup analysis from the ALpharadin in SYMptomatic Prostate CAncer patients (...

Lower Tumor Burden Patient with Progression after Sipuleucel-T, then Treated with Radium-223

Details
Lower Tumor Burden Patient with Progression after Sipuleucel-T, then Radium-223 Given with Pain Relief Independent of PSA Response Christopher Pieczonka, MD presents a case study of an mCRPC patient who achieved significant pain relief for a sustained period of time after treatment with radium-223, and whose pain was independent of the PSA. Christopher Pieczonka, MD Associated Medical Professional...

Radium-223 added to Abiraterone Acetate Treatment

Details
Radium-223 Added to Abiraterone Treatment Christopher Pieczonka, MD shares a case of a CRPC patient with bone metastases actively being treated with abiraterone acetate and during this treatment was then started on radium-223 concomitantly. Christopher Pieczonka, MD Associated Medical Professionals of NY, PLLC

mCRPC: Assessing Progression from Asymptomatic to Symptomatic Disease

Details
mCRPC: Progression from Asymptomatic to Symptomatic Disease and Approaches to Patient Treatment A review of radium-223 in the newly symptomatic mCRPC patient. The mechanism of action and radium-223 pivotal trial results are discussed. The assessment of treatment response with radium-223 is illustrated in this patient case study. Alicia K. Morgans, MD Vanderbilt Ingram Cancer Center - University Me...

Impact of Prior Docetaxel, Extent of Disease, and Prior Bisphosphonates on Hematologic Safety of Ra-223

Details
Impact of Prior Docetaxel, Extent of Disease, and Prior Bisphosphonates on Hematologic Safety of Ra-223 Professor Sartor presents a post hoc analysis of the ALSYMPCA trial evaluating the impact of prior docetaxel or bisphosphonates and extent of disease on the safety of radium-223. A. Oliver Sartor, MD Laborde Professor of Cancer Research Departments of Medicine and Urology Medical Director of Tul...

Utility of Radium-223 in Advanced Prostate Cancer

Details
Utility of Radium-223 in Advanced Prostate Cancer Leonard Gomella, MD, FACS discusses the use of radium-223 in CRPC patients with bone metastases, and how it significantly prolongs survival and time to first skeletal-related event. Leonard G. Gomella, MD, FACS Thomas Jefferson University Hospital

Practical Application of Ra-223: Treating mCRPC

Details
Practical Application of Ra-223: Treating mCRPC E. David Crawford, MD discusses CRPC and bone disease. E. David Crawford, MD University of Colorado Health Science Center

Effect of Ra-223 on Symptomatic Skeletal Events in mCRPC

Details
Review of Lancet Oncology Article: Effect of Ra-223 on Symptomatic Skeletal Events in Patients with mCRPC Professor Sartor reviews data from a phase 3, double-blind, randomised ALSYMPCA trial and demonstrates improved survival when using radium-223 in treatment of symptomatic CRPC with a few bone metastases. A. Oliver Sartor, MD Laborde Professor of Cancer Research Departments of Medicine and Urol...

mCRPC Patient Shared Decision-making

Details
mCRPC Patient Case Review: Treatment and Sharing the Decision-making Professor Sartor walks us through his approach to treating a patient with mCRPC, who is now experiencing mild pain due to his bone metastases. A. Oliver Sartor, MD Laborde Professor of Cancer Research Departments of Medicine and Urology Medical Director of Tulane Cancer Center Tulane School of Medicine New Orleans, Louisiana